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hSummary
WHO estimates reveal that the global prevalence of viral hepatitis
may be as high as 500 million, with an annual mortality rate of up
to 1.3 million individuals. The majority of this global burden of
disease is borne by nations of the developing world with high
rates of vertical and iatrogenic transmission of HBV and HCV,
as well as poor access to healthcare.
In 2013, 3.2% of the global population (231 million individuals)
migrated into a new host nation. Migrants predominantly origi-
nate from the developing countries of the south, into the devel-
oped economies of North America and Western Europe. This
mass migration of individuals from areas of high-prevalence of
viral hepatitis poses a unique challenge to the healthcare systems
of the host nations. Due to a lack of universal standards for
screening, vaccination and treatment of viral hepatitis, the bur-
den of chronic liver disease and hepatocellular carcinoma contin-
ues to increase among migrant populations globally. Efforts to
increase case identiﬁcation and treatment among migrants have
largely been limited to small outreach programs in urban centers,
such that the majority of migrants with viral hepatitis continue to
remain unaware of their infection.
This review summarizes the data on prevalence of viral hepati-
tis and burden of chronic liver disease among migrants, current
standards for screening and treatment of immigrants and refu-
gees, and efforts to improve the identiﬁcation and treatment of
viral hepatitis among migrants.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.P
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Hepatitis B (HBV) and Hepatitis C (HCV) viruses are leading
causes of chronic liver disease and associated morbidity andJournal of Hepatology 20
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immunodeﬁciency virus.mortality globally [1]. According to WHO estimates, an estimated
500 million (1 in 12 people) are living with chronic viral hepatitis,
making HBV and HCV one of the top 10 infectious disease killers
globally [1]. At least 1.3 million deaths annually can be attributed
to chronic liver disease caused by HBV and HCV [2]. In addition,
viral hepatitis is also largely responsible for the global increase in
liver cancer. Liver cancer is now the ﬁfth most common cancer
among men globally (ninth among women) with an annual mor-
tality of at least 750,000 patients [1,3]. Since the majority of peo-
ple living with chronic viral hepatitis are asymptomatic until the
late stages of disease, estimates suggest that 40–80% of people
with chronic viral hepatitis are unaware of the infection [2].
The largest burden of morbidity and mortality from chronic liver
disease continues to be in nations of the developing world. For
example, 5–10% of the adult population in East Asia and
sub-Saharan Africa are estimated to have chronic HBV infection
[4]. These countries are also the source of a steady inﬂux of
migrants into North America and the European Union (EU),
posing unique challenges to the public health and immigration
systems in the host nations.
This review will focus on immigration in the context of the
global viral hepatitis epidemic, outlining the data on prevalence
of viral hepatitis among migrants, current standards for identiﬁ-
cation and treatment of infected individuals, and the evidence
supporting targeted screening of immigrants and refugees.How common is viral hepatitis globally?
Hepatitis B
The global prevalence of HBV is estimated to be about
350–400 million people [2]. An estimated 15–40% of chronically
infected patients will go on to develop liver cirrhosis, cancer or
liver failure [3]. HBV is responsible for up to 1.2 million deaths
annually, making it the 10th leading cause of mortality globally
[2]. Chronic HBV infection is also responsible for 60–80% of the
global burden of liver cancer, with an estimated annual mortality
of 350,000 [3].
HBV is highly prevalent (>8%) in East Asia, Paciﬁc nations and
sub-Saharan Africa (Fig. 1) [4]. 45% of the global population live in
areas of high HBV prevalence, while another 40% live in regions of
intermediate prevalence [5]. The most common route of acquir-
ing infection in these countries is perinatal transmission, or15 vol. 63 j 515–522
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Fig. 2. Global HCV Prevalence [12,42,87].
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Fig. 1. Global HBV Prevalence [1,2,87].
Public Healthduring preschool years [2]. HBV is present in blood, saliva, semen
and vaginal secretions, as well as in breast milk of infected per-
sons. HBV exposure can also occur through contaminated needles
and other medical equipment in developing countries. HBV is
more infectious through blood-borne exposure than both HCV
and human immunodeﬁciency virus (HIV). Contaminated needles
alone are thought to be responsible for 8–16 million HBV infec-
tions per year [6].
Areas of intermediate prevalence (2–7%) include parts of
Central and Eastern Europe, the Middle East, Latin America as
well as the Indian subcontinent [4]. Once again, perinatal or hor-
izontal transmission is most common in these regions.
In contrast, HBV is lower in prevalence (<2%) in North America
and Western Europe [4]. In these countries, infection is usually
spread through sexual contact or IV drug use. The risk of HBV
transmission through blood transfusion has decreased516 Journal of Hepatology 201dramatically in most Western nations with the institution of rou-
tine screening of blood products, as well as universal vaccination
programs [7]. For example, the incidence of HBV in the US has
declined by 80% from 1987 to 2004 [7]. Healthcare workers con-
tinue to be an at risk population, through exposure to infected
blood or contaminated medical equipment [8].
The route of exposure, and the age of acquisition of the infec-
tion are important determinants of the long-term sequelae of
HBV. Vaccination is a safe and effective way of decreasing the risk
of neonatal HBV infection, and is especially relevant to the
nations with high HBV prevalence [9]. The WHO recommends
universal HBV vaccination at birth in countries with high preva-
lence (>8%) [10]. However, as of 2006, only 38 of 81 (44%) high
prevalence countries reported adopting birth-dose vaccination
as part of the national immunization schedule. WHO estimates
show that in 2006, birth-dose coverage was only 36% among5 vol. 63 j 515–522
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the 62 million infants born in high prevalence nations [9]. Thus,
while vaccination is an effective preventive strategy, its full
implementation has been lacking in nations most at risk.
Hepatitis C
The global burden of HCV is estimated to be 185 million people in
2005 (prevalence 2.8%), with up to 350,000 deaths annually
[11,12]. Importantly, robust population level data is not available
in most regions with high HCV prevalence, and the available esti-
mates rely on small studies, which are prone to bias. The highest
reported prevalence of chronic HCV is in Central Asia and the
Middle East. Globally, Egypt has the highest prevalence of HCV,
with some studies reporting HCV antibody positive rates of up
to 15%, with an estimated 10% with chronic viremia (Fig. 2)
[13,14]. This high prevalence is partly due to treatment programs
for schistosomiasis with unsterilized needles, which led to high
rates of transmission of HCV [14]. As a result of iatrogenic expo-
sure, and improperly sterilized medical equipment, the incidence
of HCV in Egypt continues to be high [15]. One study estimated
the incidence of new infections to be approximately 7/1000
patient-years, leading to approximately 500,000 new infections
per year [16]. Intra-familial spread of HCV is also common in this
region, however the speciﬁc practices leading to transmission are
not well understood [17].
The largest population of HCV patients worldwide resides in
East Asia and the Indian subcontinent, with at least 100 million
HCV positive individuals in this region [15,18]. HCV prevalence
rates in South and East Asia range from 0.6% in China to 4.9% in
Pakistan [19,20]. Iatrogenic exposure, through infected blood
products or medical procedures with contaminated needles, con-
tinues to be the major mechanism of transmission of HCV in
these countries [19]. However, injection drug use (IDU) is becom-
ing an increasingly important route of transmission [21].
The prevalence of HCV in North America and Western Europe
is comparatively lower. HCV transmission in Europe and North
America is predominantly through IDU [22,23]. At least 7.3 mil-
lion people (1.1%) are estimated to be living with HCV in
Europe [24,25]. Estimates suggest that 5.2 million people are
anti-HCV positive in the United States [26]. These ﬁgures likely
underestimate the true prevalence in both regions [26]. The
implementation of blood product screening and proper disposal
and sterilization of medical waste has led to a decline in the inci-
dence of HCV in both regions [27]. In the USA, HCV incidence
dropped from an estimated 7.4/100,000 people in 1982–89 to
0.7/100,000 in 1994–2006. In contrast with the developing world,
iatrogenic outbreaks in North America and Western Europe are
uncommon, and are typically conﬁned to individual clinics using
improper sterilization technique [28].
These data reveal large differences in the prevalence of these
chronic liver diseases among migrant groups and the host
nations. In an era of increasing migration, these differences in
HBV and HCV prevalence between regions have important impli-
cations for public health agencies in host nations.Global migration statistics, countries of origin and destination
With the growing ease of air travel, and the globalization of the
world economy, mass migration has been on the upswing in
the last half of the 20th century. According to UN estimates, theJournal of Hepatology 201total number of international migrants in 2013 was 231.5 million,
making this group larger than the 5th most populous nation [29].
In 1990, 154 million people, or 2.9% of the global population were
migrants, whereas the corresponding ﬁgure for 2013 was 3.2%
[30]. These numbers do not include undocumented migrants or
trafﬁcked persons, and therefore likely underestimate the global
migrant population. Many of these migrants move into and
remain part of ethnic minority groups where traditional social
and cultural behaviors that may have adverse implications for
exposure to HBV and HCV are reinforced and persist.
In 2013, the United States, Canada and four EU states
(Germany, UK, France and Spain) were among the top 10 destina-
tions for international migrants [30]. The EU was home to 72 mil-
lion foreign-born migrants in 2013, while the US alone was home
to 45 million migrants. Refugees accounted for 7% (15.7 million)
of the global migrant stock in 2013 [29].
Migration to EU and North America occurs mainly from coun-
tries with high prevalence of viral hepatitis. For example, China,
India and Philippines are among the top-10 countries of origin
to both North America as well as the EU [30]. The US is also home
to a substantial population of Mexican immigrants, and the EU
hosts large migrant populations from Turkey and Morocco
[31,32].Prevalence of viral hepatitis among migrants
The National Health and Nutritional Examination (NHANES) sur-
vey estimated that 0.3% of American residents, or about 800,000
individuals were positive for HBsAg [33]. This survey likely
under-represents the true prevalence of HBV in the US, since it
excludes high-risk populations such asmigrants, incarcerated per-
sons, homeless and veterans [7]. Currently, data on the HBV sero-
prevalence among migrants is not recorded systematically in the
US. However, the prevalence of HBV among migrants tends to
reﬂect the prevalence in their country of origin. Surveys performed
in migrant populations show very high HBV seroprevalence rates.
For example, a survey of over 4300 Asian immigrants to New York
City showed that 13% of this cohort was HBsAg positive [34].
Similarly, a study of Somali immigrants in Minnesota showed
HBV prevalence rates of ten times the baseline population [35].
Given these data, the true prevalence of HBV in the US has been
estimated to be as high as 2.2 million individuals, with up to
1.3 million foreign-born HBV positive individuals [36].
Data from the EU reveal a similar pattern, with regional vari-
ations. HBV prevalence is higher in Eastern European nations
such as Turkey (8%), Romania (6%) and Bulgaria (4%), when com-
pared to Western European nations such as Netherlands (<0.5%),
Italy (1%) and Germany (1%) [37]. HBV and HCV seroprevalence
data is now being collected by the European Centre of Disease
Prevention and Control [37], although reporting has been poor
from many member countries [38]. Pooled estimates of chronic
HBV prevalence data from ECDC surveys indicate that 53% of
HBV carriers were born outside the EU. In the Netherlands, where
robust population level data has been available, 77% of chronic
HBV infections are estimated to originate from outside the EU,
predominantly from high and intermediate prevalence regions
[39]. Studies from at least seven EU nations have shown that
the prevalence of HBV is higher in the immigrant population than
in the indigenous population. A meta-analysis on HBV prevalence
among immigrants found that prevalence rates among migrant5 vol. 63 j 515–522 517
Table 1. Current guidelines for testing and treatment of immigrants and refugees at risk for viral hepatitis.
Immigrants Refugees and Undocumented Migrants
USA No routine HBV and HCV testing
HBV vaccination for children <18 years
Positive screen does not meet inadmissibility criteria
HBsAg testing if HBV prevalence >2% in country of origin
HBsAg testing if HBV prevalence <2% and risk factors (eg., 
IDU, household contact of HBV positive person)
HCV screening if 1945-65 cohort or risk factors for HCV (eg., 
IDU)
Positive screen does not meet inadmissibility criteria
Canada History and physical to screen for risk factors, history of 
liver disease, HIV, tuberculosis or syphilis - testing if any 
of these present
Positive screen does not meet inadmissibility criteria
Same as for immigrants
Positive screen does not meet inadmissibility criteria
European 
Union
HCV and HBV screening guidelines are country-specific
Mandatory HBV/HCV testing is not required as a condition of entry
24 EU countries have universal HBV vaccination targeted at infants and adolescents 
Six countries (Denmark, Finland, Iceland, Norway, Sweden and United Kingdom) have targeted vaccination of high-risk 
groups only
Some countries with low HBV prevalence screen immigrant mothers from high-prevalence regions and offer newborn 
vaccination
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Public Healthpopulations mirror the prevalence in the country of origin, with
particularly high prevalence (>10%) among migrants from East
Asia and sub-Saharan Africa [40].
The prevalence of HCV antibody in the US may be at least
5.2 million according to one estimate, when high-risk groups
such as incarcerated and homeless individuals are taken into
account [26]. However, this estimate did not include immigrants
with HCV, so that the true prevalence of HCV in the US is likely
even higher. Data on the prevalence of HCV among US immi-
grants and refugees is sparse. However, small studies of migrant
communities have found very high HCV seropositivity rates. For
example, a hepatitis screening program enrolled 283 New
Yorkers from the former Soviet Union, 28.3% of whom were
anti-HCV positive. In Canada, immigrants are estimated to
account for at least 20% of all cases of HCV, with an estimated
prevalence of 3% in this group (general population prevalence
estimated at 0.8%) [41]. The prevalence in some groups, such as
immigrants from Egypt is reported to be as high as 18%.
HCV prevalence among EU member states is estimated to be
1% overall [42]. However, some regional differences do exist.
Anti-HCV prevalence is lowest in the Scandinavian countries
(<0.5%), but higher in Italy, Greece and Romania (>3%) [37].
ECDC data on the prevalence of HCV among migrants is limited
due to incomplete records from many member states. However,
studies in individual countries do suggest that immigrants may
constitute a high-risk group. For example, a modeling study from
the Netherlands estimated the 50% of the HCV burden in the
Netherlands occurred in immigrants, with prevalence 10-fold
higher than the native population (2% vs. 0.2%) [43]. Data from
the UK show that HCV prevalence among South Asians, and espe-
cially among migrants from Pakistan may be as high as 2.7%,
while 0.5% of the general population is estimated to have chronic
HCV [44].
In summary, migrant populations have higher rates of chronic
viral hepatitis than the local population in both North America
and the EU. These data have prompted various national and
regional guidelines for screening of migrants at high-risk for
HBV and HCV, especially in host nations that attract the largest
numbers of immigrants globally. The European, Canadian and
American guidelines for HBV and HCV screening will be summa-
rized below.518 Journal of Hepatology 201Current standards for screening of immigrants and refugees
The American immigration medical exam does not include rou-
tine testing for viral hepatitis [45]. Importantly, HBV or HCV pos-
itive serology does not meet grounds for inadmissibility to the
US. Under the current regulations, medical assessment includes
a review of prior medical history, drug and alcohol use as well
as a physical examination (Table 1). However, routine HBV and
HCV testing is not required as part of the immigration medical
exam. Age-appropriate vaccination recommendations do include
routine HBV vaccination for children below 18 years of age [46].
On the other hand, the examination of refugees on arrival to
the US includes assessment for the risk of viral hepatitis [47].
Current guidelines recommend HBsAg testing for all refugees
arriving from countries with an HBV prevalence of 2% or higher.
In addition, refugees arriving from countries with HBV preva-
lence less than 2% are also screened if they have risk factors (such
as homosexual men, IDU, household contacts of known carriers).
HBV vaccination is recommended in non-immune adults.
Recommendations for HCV testing are similar to the US popula-
tion, and include universal testing of the 1945–1965 birth cohort,
as well as testing of individuals with risk factors (such as IDU, HIV
positive individuals, and recipients of blood products). Patients
found to be positive for HBV or HCV are referred to a physician
with expertise in management of viral hepatitis.
Similar to the US immigration medical exam, universal testing
for viral hepatitis is not mandated in Canada, even in patients
originating from countries with high prevalence [48]. Rather than
screening of immigrants based on country of origin, the immigra-
tion medical exam requires identiﬁcation of risk factors for viral
hepatitis and evidence of liver disease on history and physical
examination. Patients with positive risk factors, history of liver
disease, HIV, tuberculosis or syphilis require mandatory HBV
and HCV testing. Refugee claimants are also mandated to
undergo an immigration medical examination with the same
standards. A positive HBV or HCV test does not meet grounds
for inadmissibility into Canada.
Immigration medical screening policies in the EU region are
country-speciﬁc. However, hepatitis screening is currently not
required as a condition of entry into the EU region. According
to ECDC statistics, 24 out of 30 EU/EFTA countries have adopted5 vol. 63 j 515–522
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universal HBV vaccination targeted at infants, adolescents or both
[38]. Six countries (Denmark, Finland, Iceland, Norway, Sweden
and United Kingdom) have targeted vaccination of high-risk
groups [37]. Targeted screening and vaccination of immigrants
is not performed universally in the EU, but some countries with
low-prevalence of HBV have developed programs to screen preg-
nant mothers from high prevalence regions and vaccinate their
newborns [49,50]. The optimal vaccination strategy continues
to be debated [49], but the success of these programs depends
on identiﬁcation of at-risk individuals and broad implementation
of vaccination. With high rates of HBV prevalence among immi-
grants, horizontal transmission to uninfected and unvaccinated
individuals remains a concern, in addition to high rates of vertical
transmission.P
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Studies show that the awareness of chronic HBV or HCV in most
populations is low but that among migrants it tends to be even
lower [51]. This is likely due to a combination of factors, includ-
ing poor knowledge of the diseases, their risk factors and symp-
toms, lack of access to healthcare and health information,
stigma associated with disease, as well as the lack of symptoms
from the early stages of liver disease such as viral hepatitis
[52,53]. Estimates from Canadian studies show that immigrants
and refugees are 2–5 times more likely to die from liver disease
than the baseline population [54]. A study from Ontario,
Canada showed that Hepatitis B and C were both among the
top ﬁve infectious causes of health-adjusted life years lost
(HALY’s) in the province, responsible for 18% of the total HALYs
lost [55]. While the incidence of both acute HBV and HCV infec-
tion in Canada has dropped, the prevalence of chronic viral hep-
atitis has remained stable, owing mainly to the ongoing inﬂux of
migrants from high prevalence nations [56].
Migrants are also more likely to develop hepatocellular carci-
noma (HCC). Studies from both Canada and the US show that the
incidence of HCC in migrant cohorts is at least 2–3 fold higher
than the baseline population [57,58]. In addition, mortality from
HCC is also higher in immigrant cohorts than their native-born
counterparts [54,59]. Among immigrants with HBV, the onset of
HCC tends to occur at a younger age than in the baseline popula-
tion, and especially so among patients with a family history of
HCC [60].
Thus, migrants are disproportionately afﬂicted with both
increased mortality and morbidity from chronic viral hepatitis,
and this trend is expected to continue over the next decade with
implications for costs to the healthcare system [2]. In the US,
where migrants constitute the majority of people with HBV, out-
patient and inpatient visits for HBV have increased 4-fold over the
last two decades [7]. During this period, direct healthcare costs for
HBV have risen from $350 million in 1990 to over $1.5 billion in
2003. Costs for HBV antivirals have also increased at 50% per year,
and were estimated at $82 million annually in 2008.Improving case identiﬁcation and treatment among migrants
Studies have identiﬁed patient factors such as lack of knowl-
edge, late presentation and poor adherence to follow-up and
fear of the side effects of treatment as major barriers forJournal of Hepatology 201effective treatment of viral hepatitis [61,62]. In addition, limited
knowledge of natural history, treatment options and fear of side
effects remain barriers among primary care providers treating
patients with viral hepatitis [63]. Identiﬁcation of barriers to
treatment is critical since studies show that improving sus-
tained virological response (SVR) rates is not enough to improve
HCV eradication rates without a concurrent increase in treat-
ment uptake [64].
In response to these barriers, various outreach programs have
been developed in order to educate, screen, vaccinate and offer
treatment to migrants at risk for viral hepatitis [34,65–70].
Successful campaigns, such as the BFreeNYC project, have com-
bined education and awareness initiatives with screening events
in order to both educate and identify migrant populations most at
risk of viral hepatitis [71]. Over four years, this program reached
one million people, educated 11,000 and screened 9000 Asian
migrants living in New York City. Other initiatives have aimed
at educating primary care providers, in order to improve their
knowledge and comfort with managing viral hepatitis and its
complications [72,73]. In order to be successful, outreach pro-
grams require buy-in from the target community, ongoing efforts
to raise awareness, and a linkage to care for screen-positive indi-
viduals [74]. Different approaches are usually needed for partici-
pants with different ethnic background. For example, outreach
programs targeting South Asians migrants for viral hepatitis
screening have enlisted the support of local religious organiza-
tions and community leaders in order to raise awareness in the
community [75]. Unfortunately, many outreach programs are
hampered by the high cost of screening, and lack of funding for
antiviral treatment, especially for uninsured individuals.
Estimates suggest that 31 US outreach programs active in 2008
screened only 21,000 individuals [74]. Studies on viral hepatitis
treatment rates and efﬁcacy among immigrants are limited
[76–78]. One Italian study showed that immigrants were signiﬁ-
cantly less likely than Italian-born patients to receive HBV antivi-
ral therapy [76]. However, other studies have shown no
difference in treatment uptake rates among immigrants [79].
Lack of insurance coverage [34] and lack of access to specialist
physicians [78] were felt to be barriers to treatment in some
studies. Therefore, a concerted system-wide approach is required
to identify and treat a signiﬁcant proportion of migrants with
viral hepatitis, in order to reduce the burden of chronic liver dis-
ease in this population.
Universal screening of migrants for viral hepatitis has been
evaluated by several modeling and cost-effectiveness studies
[37,41,59,80,81]. These studies have shown that screening immi-
grants from intermediate or high prevalence nations for HBV is
likely to be cost effective, and may reduce liver–related mortality
and morbidity [59,80]. Estimates for the cost per quality adjusted
life year (QALY) range from €9000 in a Dutch study proposing one
time screening for immigrants, to $39,000 in an American study
proposing screening, treatment and vaccination of contacts
among Asian migrants [59,80]. Based on these data, experts have
made recommendations for the implementation of screening pro-
grams for HBV targeting immigrants and refugees [37,47,59].
However, these recommendations have not yet been adopted
by government agencies.
The cost-effectiveness of universal screening of migrants for
HCV is not as clearly established, since HCV prevalence varies
widely among host nations and migrant groups. Studies on
cost-effectiveness of HCV screening have focused on high-risk5 vol. 63 j 515–522 519
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groups such as IDU patients, or speciﬁc birth-cohorts, such as the
1945–65 US birth cohort [82–84]. These studies suggest targeted
screening of high-risk groups is likely to be cost effective, even
with the added costs of the new DAAs. The cost-effectiveness of
screening for HCV among migrants is likely to depend on the
expected HCV prevalence in the particular cohort, treatment
uptake rates, and expected SVR [85]. Younossi et al. have esti-
mated that screening in the US would be cost effective at a
threshold prevalence of 3% if 50% of the patients started treat-
ment [86]. Based on this data, experts in Canada have recom-
mended screening among migrant populations with HCV
prevalence above 3% [41]. With the development of several
interferon-free treatment regimens for HCV, treatment options
have expanded, and expected SVR rates have improved. Thus,
more studies are needed to assess the cost-effectiveness of HCV
screening in immigrant populations with the currently available
treatment options.Conclusion
Viral hepatitis is a common and growing public health problem
worldwide. Liver cirrhosis and HCC caused by chronic HBV and
HCV infection are responsible for more than one million deaths
annually. While the majority of this burden of illness is experi-
enced in the developing world, the migration of large numbers
of people from high prevalence countries is changing disease bur-
den proﬁles in Europe and North America. The implications of
this for the planning and management of national viral hepatitis
prevention, diagnosis and treatment are considerable and call for
action. A large proportion of the burden of chronic liver disease in
developed countries is now being borne by migrants who may
not have good access to the type of services they need and could
use. Thus despite improved vaccination for HBV in many (but not
all) European countries and better hygiene measures, the inci-
dence of new cases of both HBV and HCV is increasing in the con-
text of migration. Unfortunately, routine screening of migrants
for viral hepatitis is not being performed in the majority of host
nations despite the fact that multiple studies suggest that tar-
geted screening of migrants is likely to be cost-effective, espe-
cially in the case of HBV. Efforts to alter the course of the viral
hepatitis epidemic must take up the case of migration from coun-
tries where HBV and HCV are common. National programs to deal
with the challenge will have to address the linguistic, cultural,
social and medical insurance barriers that are faced by migrants
with viral hepatitis.Conﬂict of interest
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